Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Ascelia Pharma - Presentation of H1 2025 Results

Af HC Andersen Capital
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Join us for a live presentation with Deputy CEO Julie Waras Brogren from Ascelia Pharma on 22 August 2025 at 10:00 AM CEST when she presents the financial results for H1 2025. You will have the opportunity to ask questions and gain insights into the company’s latest developments.

During the quarter, Ascelia Pharma participated in several conferences and presented Phase 3 data on Orviglance®. As previously communicated, the company expects to submit the New Drug Application (NDA) for Orviglance to the FDA following the end of the half-year period.

About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates in clinical development – Orviglance® (Mangoral) and Oncoral. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 10.39, 8 July 2025.

Seneste videoer

UPM and Sappi are planning a joint venture in graphic papers
04.12.2025, 13.00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
04.12.2025, 11.32 GreenMobility
Systemair, Audiocast, Q2'25/26
04.12.2025, 09.00 Systemair
HCA Morgenbørs 03/12 - Overvejende positive futures og fokus på ISS
03.12.2025, 09.23 Novo Nordisk
Hafnia – Presentation of the quarterly report for Q3 2025
02.12.2025, 11.00 Hafnia
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.